Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
iCAD, Inc. specializes in advanced cancer detection and treatment solutions, particularly in breast and prostate cancer. With a focus on AI-driven imaging and radiation therapy technologies, iCAD's proprietary products, such as the ProFound AI platform, provide unique diagnostic capabilities that enhance accuracy and efficiency in clinical settings.
iCAD generates revenue primarily through the sale of its imaging and radiation therapy devices, which are often sold with recurring software and service contracts. The company's competitive advantage lies in its proprietary AI algorithms that improve diagnostic accuracy, thus driving demand from healthcare providers seeking to enhance patient outcomes.
Adoption rates of ProFound AI in hospitals and imaging centers
Regulatory approvals for new products
Partnerships with healthcare providers and technology firms
Trends in cancer diagnosis and treatment demand
Technological disruption from emerging imaging technologies
Regulatory changes affecting medical device approvals
Increased competition from established medical device companies
Emergence of new entrants with innovative AI diagnostic tools
Negative operating cash flow could limit operational flexibility
High reliance on continued investment in R&D without immediate revenue returns
moderate - iCAD's performance is somewhat linked to healthcare spending, which can be influenced by economic cycles and consumer confidence.
Higher interest rates could increase financing costs for iCAD's operations and limit capital expenditures by healthcare providers, potentially dampening demand for its products.
minimal - iCAD's low debt levels (Debt/Equity of 0.01) suggest it is not heavily reliant on credit markets.
growth - investors are likely drawn to iCAD for its potential in the rapidly evolving medical technology sector.
high - historical volatility is elevated due to the company's small market cap and reliance on product approvals.